Literature DB >> 23438846

Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.

M J Molina-Garrido, C Guillen-Ponce, A Mora-Rufete1.   

Abstract

Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23438846     DOI: 10.2174/18715206113139990087

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.

Authors:  Peter Dall; Thorsten Koch; Thomas Göhler; Johannes Selbach; Andreas Ammon; Jochen Eggert; Nidal Gazawi; Daniela Rezek; Arthur Wischnik; Carsten Hielscher; Stella Keitel; Ursula Cirrincione; Axel Hinke; Gabriele Feisel-Schwickardi
Journal:  Oncologist       Date:  2017-02-07

2.  Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.

Authors:  Peter Dall; Thorsten Koch; Thomas Göhler; Johannes Selbach; Andreas Ammon; Jochen Eggert; Nidal Gazawi; Daniela Rezek; Arthur Wischnik; Carsten Hielscher; Nicolas Schleif; Ursula Cirrincione; Axel Hinke; Gabriele Feisel-Schwickardi
Journal:  BMC Cancer       Date:  2018-01-08       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.